Veru Inc. (NASDAQ: VERU), the stock kept on staying up 16.35% to $11.28 in after-market as the biotech oncology company focusing on the development of novel prostate and breast cancer management medicines, unveils positive Phase 2 clinical trial results for the selected oral, novel selective androgen receptor (AR) targeting agent enobosarm for the treatment of endocrine and chemotherapy-resistant ER+/HER2 metastatic breast cancer.
In 85% of all breast cancers, oestrogen receptor (ER) is present, and more than 90% of ER+ positive breast cancers also contain AR, which is a significant therapeutic target for ER+ breast cancer. Enobosarm is an oral drug that selectively targets AR in breast cancer without harmful side effects of unwanted virilizing androgen including facial hair, acne, hematocrit increase, or liver toxicity while having potential clinical benefits including increasing muscle and physical function as well as addressing bone loss and fractures induced by cancer treatment. Having been assessed in 25 separate research trials with 2,091 patients treated, including three Phase 2 advanced breast cancer clinical trials, Enobosarm has substantial non-clinical and clinical experience.
As we reported yesterday, during the premarket the stock was surging following its quarterly results announcement.